Meridian Biopharmaceuticals focuses on the development of innovative cancer therapeutics, with emphasis on monoclonal antibody therapy and multi-epitope cancer vaccines.

Cancer is one of the leading causes of death in industrial countries and the second major killer worldwide besides cardiovascular disease. Meridian's therapeutic concept is to destroy cancer cells with metastatic potential.

Meridian Biopharmaceuticals focuses on the development of monoclonal antibodies (MB311 and MB314) that are specific for the tumor-associated carbohydrate antigen Lewis Y which is over-expressed at a broad variety of epithelial cancer types. Upon binding to cancer cells, the cellular signaling process is inhibited and complement and antibody-dependent cellular cytotoxicity are mediated resulting in the destruction of the malignant cell. In particular, circulating tumor cells which have the potential to form distant metastasis' and are often the cause of death are targeted.

Furthermore, Meridian Biopharmaceuticals has developed a Humira™ Biosimilar (MB612). Humira™ is the trade name of Adalimumab, a monoclonal antibody that binds to soluble TNFα . Currently, Humira™ is one of the best-selling therapeutic antibodies and Biosimilars will be allowed in the US by 2018.